Topic: Sham litigation

Sanofi denies abuse of FDA’s Orange Book

Sanofi-Aventis says that Mylan Pharmaceuticals’ allegations that it illegally cornered the market for long-lasting insulin are merely a mishmash of “antitrust buzz words”.

19 September 2023